Article Text

Download PDFPDF
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
  1. K Jirström1,
  2. L Rydén1,
  3. L Anagnostaki1,
  4. B Nordenskjöld2,
  5. O Stål2,
  6. S Thorstenson3,
  7. G Chebil4,
  8. P-E Jönsson5,
  9. M Fernö6,
  10. G Landberg1
  1. 1Division of Pathology Department of Laboratory Medicine, Lund University, Malmö University Hospital, SE-205 02, Malmö, Sweden
  2. 2Department of Biomedicine and Surgery, Division of Oncology, Linköping University, SE-581 83 Linköping, Sweden
  3. 3Department of Pathology and Cytology, Kalmar County Hospital, SE-391 85 Kalmar, Sweden
  4. 4Department of Pathology, Helsingborg Hospital, SE-251 87 Helsingborg, Sweden
  5. 5Department of Surgery, Helsingborg Hospital
  6. 6Department of Oncology, Lund University Hospital, SE-221 85 Lund, Sweden
  1. Correspondence to:
 Dr K Jirström
 Division of Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, SE-205 02, Malmö, Sweden;


Background: Subgroups of breast cancer that have an impaired response to endocrine treatment, despite hormone receptor positivity, are still poorly defined. Breast cancer can be subdivided according to standard pathological parameters including histological type, grade, and assessment of proliferation. These parameters are the net result of combinations of genetic alterations effecting tumour behaviour and could potentially reflect subtypes that respond differently to endocrine treatment.

Aims: To investigate the usefulness of these parameters as predictors of the response to tamoxifen in premenopausal women with breast cancer.

Materials/methods: Clinically established pathological parameters were assessed and related to the tamoxifen response in 500 available tumour specimens from 564 premenopausal patients with breast cancer randomised to either two years of tamoxifen or no treatment with 14 years of follow up. Proliferation was further evaluated by immunohistochemical Ki-67 expression.

Results: Oestrogen receptor positive ductal carcinomas responded as expected to tamoxifen, whereas the difference in recurrence free survival between control and tamoxifen treated patients was less apparent in the relatively few lobular carcinomas. For histological grade, there was no obvious difference in treatment response between the groups. The relation between proliferation and tamoxifen response seemed to be more complex, with a clear response in tumours with high and low proliferation, whereas tumours with intermediate proliferation defined by Ki-67 responded more poorly.

Conclusions: Clinically established pathology parameters seem to mirror the endocrine treatment response and could potentially be valuable in future treatment decisions for patients with breast cancer.

  • BCS, breast cancer survival
  • ER, oestrogen receptor
  • IDC, invasive ductal carcinomas
  • ILC, invasive lobular carcinoma
  • MI, mitotic index
  • NHG, Nottingham histological grade
  • PR, progesterone receptor
  • RFS, recurrence free survival
  • breast cancer
  • oestrogen receptor
  • proliferation
  • lobular breast cancer
  • tamoxifen

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • On behalf of the South Swedish and South-East Swedish breast cancer groups.